Our Website Uses Cookies 

We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.

For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Covington Advises Procter & Gamble in Alliance with ARYx Therapeutics

July 20, 2006

SAN FRANCISCO, July 20, 2006  -  The San Francisco office of Covington & Burling LLP advised Procter & Gamble Pharmaceuticals, Inc., a division of The Procter & Gamble Company, in its strategic alliance with ARYx Therapeutics, a private drug discovery and development company based in Fremont, CA.  Under the terms of the agreement, P&G will develop and commercialize ARYx's novel drug, ATI-7505, for the treatment of gastrointestinal disorders such as gastroesophageal reflux disease (GERD) and gastroparesis.

ARYx will grant P&G rights for the worldwide development and commercialization of ATI-7505 in exchange for a $25 million upfront fee, milestone payments, and royalties on product sales according to the terms of the deal. In addition, ARYx will retain an option to co-develop and co-promote ATI-7505.   In total, payments could reach $435 million over the life of the project, including $250 million that could be earned prior to commercialization.

The Covington team included Jim Snipes, Amy Toro and Chelsea Tanaka-Delgado, all in Covington's San Francisco office.

Share this article: